C-myc analysis of oral squamous cell carcinoma in Taiwan area

• Main Authors: Ya Chi Chiang, 江亞錡
• Other Authors: S. D. Cheng
• Format: Others
• Published: 2014
• Online Access: http://ndltd.ncl.edu.tw/handle/70845035571640236761

碩士 === 長庚大學 === 生物醫學研究所 === 102 === The mechanism among different genes and their proteins involving the various stages of oral squamous cell carcinoma (OSCC) is still under investigation either domestic or worldwide. We examined the copy number of c-myc gene and the amount of its protein in the tumor cells of 157 cases, whose clinicopatholgical data were statistically analyzed with, so as to understand the impact to the survival time of postsurgery patients. Judging from the result of fluorescent in situ hybridization, the c-myc copy number may be regarded as a biomarker of postsurgical survival time of OSCC patients. One hundred and nineteen cases (75.8%) were analyzed to be monosomy or disomy, while 38 cases (24.2%) showed polysomy or gene amplification. The difference between the overall survival times of two groups is obvious, 66.5±3.5 vs. 42.8±5.1 months (p=0.033); while that of the disease free survival times too, 50.9±3.0 vs. 37.9±5.6 months (p=0.062). The difference of the ratio of polysomy or gene amplification shown in the lymph node metastasis cases, 32.3% (21 out of 65 cases), comparing with that of non-metastasis cases, 18.5% (17 out of 92 cases) is high (p=0.046). The difference of those ratios between the cases with larger tumor (≧4 cm) (29.2%, 21 out of 72 cases) and with smaller tumor (< 4 cm) (17.3%, 13 out of 75 cases) is also high (p=0.089). Shown with immunohistochemistry method, among 43 cases with tumor cells invading nerve bundles 21 cases (69.8%) demonstrated positive result (p=0.092). Judging from the morphology of the tissue, there is no difference between the vi monosomy/disomy group and polysomy/amplification group. However, the overall survival time of the patients with the c-myc gene amplification is less than one year. This may be a biomarker for the prognosis of the OSCC patients.